Answers are grounded in this paper and cite their sources.
Genetic testing for cancer susceptibility is already part of the clinical management of families with some of the well-defined (but uncommon) inherited cancer syndromes. In cases where the risks associated with a predisposing mutation are less certain, or where there is no clearly effective intervention to offer those with a positive result, its use is more controversial. Careful evaluation of costs and benefits, and of the efficacy of interventions in those found to be at risk, is essential and is only just beginning. An immediate challenge is to ensure that both health professionals and the public understand clearly the issues involved.
No takes yet. Share an insight, caveat, or question.
Bruce A.J. Ponder (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: